

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CF PharmTech, Inc. **長風藥業股份有限公司**

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2652)

VOLUNTARY ANNOUNCEMENT **INHALATION FORMULATION PRODUCTION BASE PASSED** **GMP INSPECTION IN A PIC/S MEMBER COUNTRY**

This announcement is made by CF PharmTech, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Group’s inhalation formulation production base in Suzhou, China (the “**Base**”) has recently passed an on-site good manufacturing practice (the “**GMP**”) compliance inspection conducted by the drug regulatory authority of a member country of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (the “**PIC/S**”). The inspection examined the Base’s production management and quality control systems, premises, facilities and equipment, data integrity and computerised systems.

Passing the inspection confirms that the Base’s quality management system and production capacity meet PIC/S GMP standards, opening a key market access channel for the Group’s inhalation formulations. The target market has a population of hundreds of millions and a high burden of chronic respiratory disease, including asthma and chronic obstructive pulmonary disease (COPD), where local access to inhalation formulations remains below the international average.

The Group has previously obtained China GMP certification and passed European Union Qualified Person (QP) audits. This latest clearance in a PIC/S member country marks a further milestone in the Group’s global expansion and supports its strategy of supplying high-quality inhalation formulations and cost-effective respiratory disease solutions to overseas markets.

RISK WARNING

The GMP compliance inspection relates to the manufacturing quality management system of the Base. While passing the inspection confirms that the Base meets the relevant PIC/S GMP standards, it does not by itself guarantee that the Group’s products will be registered, approved for import or sale, or commercialised in the target market, which remains subject to applicable product registration and import requirements, commercial arrangements and prevailing market conditions. Accordingly, there is no assurance as to whether or when the Group’s inhalation formulations will be launched in that market. **Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

ABOUT THE COMPANY

As a global innovator in inhalation drug delivery technology, CF PharmTech, Inc. is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is not only a specialist in the development of complex inhalation formulations with high barriers to entry, but also a platform-based innovative pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, global regulatory filing and commercialization.

Leveraging its fully self-developed, globally integrated end-to-end capabilities – from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to siRNA nucleic acid delivery platforms – the Company is systematically advancing its proprietary innovative pipeline for the markets in China, the United States and Europe. Its therapeutic areas encompass respiratory diseases (including asthma, chronic obstructive pulmonary disease and bronchiectasis) and nasal diseases (including allergic rhinitis and chronic rhinosinusitis), with strategic expansion into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections and central nervous system disorders, as the Company advances precision drug delivery via the nose-to-brain pathway.

The Company has established an extensive multi-dimensional commercialization network in China and, through its globally compliant manufacturing systems and deepening global presence, is steadily advancing towards its goal of becoming a global innovative pharmaceutical enterprise.

By order of the Board

CF PharmTech, Inc.

長風藥業股份有限公司

Dr. LIANG Bill Wenqing

Chairperson, Executive Director and Chief Executive Officer

Hong Kong, June 4, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.